Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Provided By GlobeNewswire
Last update: May 18, 2025
Slowing of progression of disease observed via MRI at 24 months
Improvements in outcomes and reduction in sorbitol maintained through 24 months
Read more at globenewswire.com0.9403
-0.11 (-10.45%)
Find more stocks in the Stock Screener
APLT Latest News and Analysis
